This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Do Options Traders Know Something About Puma Biotechnology (PBYI) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down
by Zacks Equity Research
Puma's (PBYI) shares decline after CHMP conveyed the company that the former will probably vote against the approval of breast cancer drug Nerlynx at the CHMP meeting scheduled in February.
Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?
by Zacks Equity Research
Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.
Puma (PBYI) Stock Up More than 200% This Year: Here's Why
by Zacks Equity Research
Puma's (PBYI) shares skyrocket in the year so far on the approval of its cancer drug Nerlynx in the United States coupled with strategic collaborations.
Puma Inks License Deal to Commercialize Cancer Drug Nerlynx
by Zacks Equity Research
Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.
Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss
by Zacks Equity Research
Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q3. However, shares were down in after-hours trading.
Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings?
by Zacks Equity Research
Puma Biotechnology (PBYI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND
by Zacks Equity Research
The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if some small biotechs, due to report on Nov 9, follow suit.
5 Biotech Stocks Well Poised to Surpass Expectations in Q3
by Zacks Equity Research
The pharma and biotech industry has demonstrated strength
Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?
by Zacks Equity Research
Puma Biotechnology's (PBYI) only marketed product, Nerlynx (neratinib), for advanced breast cancer was launched in August. So Q3 is the first quarter in which Puma will record sales for Nerlynx.
4 Biotech Stocks That More Than Doubled This Year
by Zacks Equity Research
The biotech sector has been witnessing an uptrend this year with impressive performance in both the quarters. Shares of quite a few companies have more than doubled so far this year riding this trend.
Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus
by Zacks Equity Research
Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q2. Shares were down in after-hours trading.
3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings
by Zacks Equity Research
The first half has been pretty strong for companies in the space.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
With Catalyst Pharmaceuticals, Inc. (CPRX) not having any marketed product in its portfolio, its focus at the Q2 conference call will be on the progress of its pipeline candidates, Firdapse, CPP-115 and CPP-109.
What's in Store for BioDelivery (BDSI) This Earnings Season?
by Zacks Equity Research
BioDelivery Sciences International (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact second-quarter results remains to be seen.
What's in the Cards for Kite Pharma (KITE) in Q2 Earnings
by Zacks Equity Research
With no approved products in its portfolio, investor focus will primarily be on Kite Pharma, Inc.'s (KITE) cash burn and pipeline updates.
Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings?
by Zacks Equity Research
Puma Biotechnology (PBYI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
Jazz Pharma's (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q2, thanks to label expansion efforts.
Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q2. However, lack of an approved product in portfolio is a dampener.
What's in Store for Puma (PBYI) this Earnings Season?
by Zacks Equity Research
Recent approval of Puma's (PBYI) lead candidate, neratinib, by the FDA might offer a huge boost to the company in Q2, though no sales from the drug will be recorded during the same.
What's in Store for Arena (ARNA) this Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive performance so far, the company's efforts to improve the drug's performance might drive the stock in Q2.
What's in the Cards for Celldex (CLDX) this Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.
Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) Nuplazid is expected to maintain the growth trend, established since its launch, in the second quarter.
Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.
GW Pharmaceuticals (GWPH) Q3 Earnings: What Lies in Store?
by Zacks Equity Research
Investors will likely be looking at GW Pharmaceuticals' (GWPH) progress with its anti-epileptic pipeline candidate, Epidiolex in its fiscal third-quarter results.